1. Home
  2. COGT vs SDHC Comparison

COGT vs SDHC Comparison

Compare COGT & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • SDHC
  • Stock Information
  • Founded
  • COGT 2014
  • SDHC 2008
  • Country
  • COGT United States
  • SDHC United States
  • Employees
  • COGT N/A
  • SDHC N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • SDHC
  • Sector
  • COGT Health Care
  • SDHC
  • Exchange
  • COGT Nasdaq
  • SDHC Nasdaq
  • Market Cap
  • COGT 1.1B
  • SDHC 933.4M
  • IPO Year
  • COGT 2018
  • SDHC 2024
  • Fundamental
  • Price
  • COGT $11.70
  • SDHC $20.19
  • Analyst Decision
  • COGT Strong Buy
  • SDHC Hold
  • Analyst Count
  • COGT 9
  • SDHC 4
  • Target Price
  • COGT $20.25
  • SDHC $23.63
  • AVG Volume (30 Days)
  • COGT 1.8M
  • SDHC 62.3K
  • Earning Date
  • COGT 08-05-2025
  • SDHC 08-06-2025
  • Dividend Yield
  • COGT N/A
  • SDHC N/A
  • EPS Growth
  • COGT N/A
  • SDHC N/A
  • EPS
  • COGT N/A
  • SDHC N/A
  • Revenue
  • COGT N/A
  • SDHC $1,013,967,000.00
  • Revenue This Year
  • COGT N/A
  • SDHC $3.34
  • Revenue Next Year
  • COGT N/A
  • SDHC $9.42
  • P/E Ratio
  • COGT N/A
  • SDHC N/A
  • Revenue Growth
  • COGT N/A
  • SDHC 22.89
  • 52 Week Low
  • COGT $3.72
  • SDHC $16.28
  • 52 Week High
  • COGT $12.97
  • SDHC $39.50
  • Technical
  • Relative Strength Index (RSI)
  • COGT 59.54
  • SDHC 54.88
  • Support Level
  • COGT $10.38
  • SDHC $17.00
  • Resistance Level
  • COGT $12.21
  • SDHC $20.35
  • Average True Range (ATR)
  • COGT 0.53
  • SDHC 1.07
  • MACD
  • COGT -0.16
  • SDHC 0.03
  • Stochastic Oscillator
  • COGT 64.13
  • SDHC 84.25

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About SDHC Smith Douglas Homes Corp.

Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.

Share on Social Networks: